GlassScriptPhysician profile
Deidre D Crocker
NPI 1790947117
$8,765.40
in general payments reported to CMS, 2019-2025
30 companies · $1,606 in 2025
The $1,606 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $639 · 2020: $336 · 2021: $25.24 · 2022: $780 · 2023: $528 · 2024: $4,851 · 2025: $1,606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,440 · Food and Beverage: $3,430 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,440.00 |
| Food and Beverage | $3,430.02 |
| Education | $115.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $4,147.48 | 2024 | Xolair |
| Glaxosmithkline, LLC. | $1,110.77 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $664.79 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $637.45 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Novartis Pharmaceuticals Corporation | $417.24 | 2019-2025 | |
| Ars Pharmaceuticals Operations, INC. | $223.97 | 2025 | Neffy |
| Alk-Abello, INC | $175.37 | 2019-2022 | |
| Amgen INC. | $166.40 | 2022-2025 | Tezspire |
| Sanofi-Aventis U.S. LLC | $157.43 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $138.40 | 2019-2025 | Dupixent |
| Biocryst US Sales Co., LLC | $107.89 | 2021-2025 | Orladeyo |
| Optinose US, INC. | $94.09 | 2019-2025 | |
| Abbvie INC. | $90.63 | 2022-2023 | Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $71.63 | 2022-2024 | Takhzyro, Hyqvia |
| Grifols USA, LLC | $71.30 | 2025 | Xembify |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $70.83 | 2023-2024 | Hizentra, Haegarda |
| Pfizer INC. | $64.57 | 2019-2024 | |
| Leo Pharma INC. | $53.68 | 2022-2024 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.51 | 2019-2020 | |
| Blueprint Medicines Corporation | $41.79 | 2025 | Ayvakit |
| Kaleo, INC. | $32.52 | 2019-2024 | Auvi-Q |
| Pharming Healthcare, INC. | $27.38 | 2024 | Ruconest |
| Lilly USA, LLC | $23.15 | 2025 | Ebglyss |
| Hikma Pharmaceuticals USA | $22.15 | 2023 | Ryaltris |
| Genentech, INC. | $21.30 | 2023 | Xolair |
| Arcutis Biotherapeutics, INC. | $19.66 | 2025 | Zoryve |
| Galderma Laboratories, L.P. | $18.88 | 2025 | Nemluvio |
| Shire North American Group INC | $18.78 | 2019 | |
| Incyte Corporation | $12.51 | 2022 | |
| Organon LLC | $11.85 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deidre Crocker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.